Takeda

Takeda announced a $230 million investment to expand production capacity for plasma-derived therapies at its Los Angeles manufacturing site, creating over 125 new long-term jobs.

Takeda will invest €100 million by 2025 in its Linz, Austria production site, including a new syringe production line for biologics treating chronic inflammatory bowel diseases. The line is expected to start production in fiscal year 2024.

Takeda announced a long-term investment of approximately 100 billion yen to build a new plasma-derived therapy manufacturing facility at its Osaka plant in Juso, Japan. The facility will have a plasma processing capacity of over 2 million liters per year and is expected to start operations around 2030.

Takeda announced an investment of close to 300 million euros to expand its biotechnology manufacturing site in Lessines, Belgium, with a new production facility and a net-zero carbon emissions warehouse.

Takeda has tripled the production capacity of its plant in Tres Cantos, Madrid, for the allogeneic cell therapy for Crohn's disease, with a €10.6 million investment.

Takeda announced a $126 million investment at its California facility.

Takeda completed the sale of its TachoSil Fibrin Sealant Patch to Corza Health for €350 million ($422.4 million) in cash. The deal includes assets and licenses for development and commercialization, while Takeda retains the manufacturing facility in Linz, Austria.

GTCR and former NuVasive CEO launched Corza Medical by acquiring Surgical Specialties and merging it with TachoSil, a carve-out from Takeda, creating a surgical technologies company with over $300 million in revenue.